These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33432541)

  • 1. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review.
    Cella D; Evans J; Feuilly M; Neggers S; Van Genechten D; Herman J; Khan MS
    Adv Ther; 2021 Feb; 38(2):969-993. PubMed ID: 33432541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.
    O'Toole D; Kunz PL; Webb SM; Goldstein G; Khawaja S; McDonnell M; Boiziau S; Gueguen D; Houchard A; Ribeiro-Oliveira A; Prebtani A
    Adv Ther; 2023 Feb; 40(2):671-690. PubMed ID: 36502449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review.
    Boguszewski CL; Korbonits M; Artignan A; García AM; Houchard A; Ribeiro-Oliveira A; de Herder WW
    Endocrine; 2023 Mar; 79(3):527-536. PubMed ID: 36369434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).
    Adelman D; Truong Thanh XM; Feuilly M; Houchard A; Cella D
    Adv Ther; 2020 Apr; 37(4):1608-1619. PubMed ID: 32157626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.
    Schopohl J; Strasburger CJ; Caird D; Badenhoop K; Beuschlein F; Droste M; Plöckinger U; Petersenn S;
    Exp Clin Endocrinol Diabetes; 2011 Mar; 119(3):156-62. PubMed ID: 21086246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
    Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
    J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly.
    Fleseriu M; Zhang Z; Hanman K; Haria K; Houchard A; Khawaja S; Ribeiro-Oliveira A; Gadelha M
    Pituitary; 2023 Feb; 26(1):9-41. PubMed ID: 36447058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
    Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors.
    Seo C; Horodniceanu E; Shah R; Goldstein G; Ray D; Bennett B; Phan A; McCarrier K
    Support Care Cancer; 2022 Jul; 30(7):6307-6316. PubMed ID: 35476113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Arsof-Saab IN; Castellanos-Moreno CA; Botero L; Triana L
    J Endocrinol Invest; 2023 Jan; 46(1):27-35. PubMed ID: 35913681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
    Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
    Adv Ther; 2022 Apr; 39(4):1754-1771. PubMed ID: 35190997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lanreotide autogel in acromegaly - a decade on.
    Kyriakakis N; Chau V; Lynch J; Orme SM; Murray RD
    Expert Opin Pharmacother; 2014 Dec; 15(18):2681-92. PubMed ID: 25307803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
    Ludlam WH; Anthony L
    Adv Ther; 2011 Oct; 28(10):825-41. PubMed ID: 21964965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
    Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies.
    Adelman DT; Van Genechten D; Megret CM; Truong Thanh XT; Hand P; Martin WA
    Adv Ther; 2019 Dec; 36(12):3409-3423. PubMed ID: 31612358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey.
    Hernando J; Kolarova T; Verslype C; Kaltsas G; Houchard A; Gueguen D; De Herder WW
    J Neuroendocrinol; 2023 Jun; 35(6):e13281. PubMed ID: 37290479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.
    Gurel MH; Han Y; Stevens AL; Furtado A; Cox D
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):22. PubMed ID: 28372573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.